Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders - Wikidata - awgldk - TriplyDB

Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders

Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders

http://www.wikidata.org/entity/Q33757565

about

Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis.Medical treatment overview: traditional and novel psycho-pharmacological and complementary and alternative medications Pharmacotherapy to control behavioral symptoms in children with autism The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders.Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis.A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.Treatment Options for the Cardinal Symptoms of Disruptive Mood Dysregulation Disorder Amantadine: a review of use in child and adolescent psychiatry Pharmacotherapy for the core symptoms in autistic disorder: current status of the research Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial Treatment of Autism Spectrum Disorder in Children and Adolescents.Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice.Review of the pharmacotherapy of irritability of autism.Psychopharmacology of autism spectrum disorders: a selective review.Incidence and behavioral correlates of epileptiform abnormalities in autism spectrum disorders.Autism spectrum disorders: an overview on diagnosis and treatment.An update on medication management of behavioral disorders in autism.What's in the pipeline? Drugs in development for autism spectrum disorder.Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder.Asperger's syndrome: diagnosis, comorbidity and therapy.Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies.Perinatal Influences of Valproate on Brain and Behaviour: An Animal Model for Autism.Psychopharmacological interventions in autism spectrum disorder.Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials.Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder Are there new advances in the pharmacotherapy of autism spectrum disorders?Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study.What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism?Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents.Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder.[Psychopharmacology of autism spectrum disorders].Missed connections.Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder.Anticonvulsants for Psychiatric Disorders in Children and Adolescents: A Systematic Review of Their Efficacy.

P2860

Q26776479-E43A3926-2C11-4EA6-BCBD-C185DE4BD936 Q27014201-AF2B3357-3503-4E15-81F7-0D79562246F5 Q28265801-1FA9DFE8-09DA-4576-8AD4-80C009DE6B14 Q33664736-EE28BF08-EBC2-4D11-BE16-1BEF9DE7B7B6 Q34374130-7452709C-4732-4B60-BCE7-E5A7F793D68E Q34392818-0248674A-99D8-41FA-9F32-341F15DDCE96 Q34492314-4F17468E-0433-4992-893F-1C5131D2499C Q34648021-A51B7214-ACFF-4DF9-AB54-77B097E6E1C0 Q36784208-8E7273FE-81D5-4984-8F7E-B95627C6488A Q37019876-33E72E40-144A-4328-BBE1-F6E5CADE15D7 Q37299857-87B32CD6-613D-4749-B68E-7CECA7C67E9A Q37347743-E63E086A-A7C1-40F2-A4BD-8DECBD7089DC Q37774098-E14C8C8D-AE13-4D03-8579-988ABFA36FFA Q37954157-CF307A27-5B53-4F73-A1BE-612F63C9BEF8 Q38006705-426EF241-B956-4E58-BFEB-FFB19E82264C Q38034655-EA437AA7-5DFA-4A51-B19A-76B5E1423BF3 Q38123049-70B3A484-F50E-4CAD-94EA-72BF9CB0AA96 Q38154183-557C929B-BC3B-435D-8A4A-CA5E39BBFDBF Q38184482-010E7D42-CEF2-4492-A603-2C47DA9604F2 Q38193069-19787738-881A-47BF-BD59-A8F83897C3FA Q38237334-0141DFDD-6DAF-4801-B699-6C5AACD59F1C Q38345718-F357498B-D23B-4DF4-AB24-2D463D4508D6 Q38601092-E1E1BDD2-3E2E-4945-9A68-E404EF2FEA3C Q38618627-58C4DA9D-A044-44CB-BDC8-94A0487EBEF5 Q38739577-CCF3F82C-0568-4D31-B0C8-5B18777AE3C7 Q41060924-99A7572A-7C84-4652-853F-DC1E09EB893A Q41634238-BE605D70-3088-4967-812E-66AD2495B912 Q42327831-0E2B4E95-D081-465C-B0AE-92CFC5C8CC74 Q44569444-9158AEA3-80F5-45AB-AF8D-A204FD727D42 Q47812079-7F700744-73CC-44E6-A42A-6C602E519A19 Q49332454-B8DFD412-9F9E-4160-819F-A2849A8563E6 Q50305089-DE57023A-042B-421E-A19F-42B1960A32B2 Q50311469-4806F9A4-60B8-4B87-8FDE-C43E08B395A1 Q50311533-56D22408-2540-430C-A305-4224A42BFBA1 Q55180784-8EF7953C-6946-496A-B3EC-9F3CC7859F89 Q55472201-45198325-3E9A-467A-892F-B119664001A2

P2860

Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders

http://www.wikidata.org/entity/Q33757565

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Divalproex sodium vs placebo f ...... with autism spectrum disorders

@ast

Divalproex sodium vs placebo f ...... with autism spectrum disorders

@en

type

label

Divalproex sodium vs placebo f ...... with autism spectrum disorders

@ast

Divalproex sodium vs placebo f ...... with autism spectrum disorders

@en

prefLabel

Divalproex sodium vs placebo f ...... with autism spectrum disorders

@ast

Divalproex sodium vs placebo f ...... with autism spectrum disorders

@en

P1433

Q33757565-7FDDF3BD-669C-4CE0-A2D3-34768B8FDC8D

P1476

Q33757565-B2291525-ABD6-4108-91E5-5116274B9909

P2093

Q33757565-4D3D4801-58A1-4943-85F8-E9BFA7293364

Q33757565-51911CC5-D747-4F6E-9BEE-9A3DDF609334

Q33757565-5F62CC14-09AE-406B-A979-51997279D119

Q33757565-9C860CD8-2B73-49A1-A38A-ACD2DE7D8416

Q33757565-AA824BED-09CC-4A80-B0B3-FDBA2FC75330

Q33757565-C260CFD2-D1E1-4D86-9B0E-59E1B5379780

Q33757565-E6D2D85A-38EF-4371-8185-7F1E608E2191

Q33757565-EAB1F876-9FFD-486E-99FA-EAAF5243F264

P2860

Q33757565-08671D40-4A82-4421-B950-CEAD0A7D3BE2

Q33757565-115271F4-0F3C-40EE-ABC3-99A3DE18734A

Q33757565-148823F0-B87C-4656-9D14-411E08AA66D4

Q33757565-25F944F6-657F-4268-AB17-C0330BE52840

Q33757565-340D0C08-CE1E-4F7A-BB7C-6BD9A4BA2EB6

Q33757565-37248EEC-D9AC-40B8-86CB-532E2C894678

Q33757565-3BE9925A-7ED8-4936-A3E5-0B7E17879235

Q33757565-3F5085DC-861E-402E-A69A-7004570C2AFB

Q33757565-44DA3C5B-6366-4398-8E6C-2016DA2BBFE2

Q33757565-45130E9D-198C-4E82-9DE9-D6A5E39C88A4

P2888

Q33757565-BFC85567-84A7-4BB0-9B39-2AB1D060B593

P304

Q33757565-0B0BFD50-2E1F-4DBD-8238-6B4DA8AFD59D

P31

Q33757565-5EBB03C8-692E-4DBD-B5FB-C001B3C878EC

P356

Q33757565-07B02D3B-89F4-4FDE-819A-EC08EFA6374B

P407

Q33757565-91BEEF70-57BF-4246-8CED-4AF22939DF10

P433

Q33757565-866CC11A-E6F2-4AA7-9275-895F74407368

P478

Q33757565-73827D20-C22E-4642-BFD5-3916EBB5B3AA

P50

Q33757565-E528BBEC-06B3-442D-94AA-672C6D87975E

P577

Q33757565-A173C95B-74A8-4FA7-9357-8224DF95DDE8

P5875

Q33757565-544B10BF-2A81-4DB9-8BF6-C7CC61378B7B

P6179

Q33757565-77362242-E17F-467E-8C48-878D4580B754

P698

Q33757565-87D2098B-CF05-4008-8D51-A033F1BD24FD

P921

Q33757565-1023C811-BE22-4DB0-A0FD-4508101ADEE0

Q33757565-8AECEC93-BD3F-4FA9-B413-4C3463B25C02

Q33757565-D810BA31-0C45-4ECB-AC42-909053C0CEB7

P932

Q33757565-704870FA-2737-4921-95D7-B7C3B2DC86D4

P356

P1433

Neuropsychopharmacology

P1476

Divalproex sodium vs placebo f ...... with autism spectrum disorders

@en

P2093

Eric Hollander

http://www.w3.org/2001/XMLSchema#string

Jade Rusoff

http://www.w3.org/2001/XMLSchema#string

Latha Soorya

http://www.w3.org/2001/XMLSchema#string

Lauren Pepa

http://www.w3.org/2001/XMLSchema#string

Nicole Feirsen

http://www.w3.org/2001/XMLSchema#string

Sherry Novotny

http://www.w3.org/2001/XMLSchema#string

Stacey Wasserman

http://www.w3.org/2001/XMLSchema#string

William Chaplin

http://www.w3.org/2001/XMLSchema#string

P2860

Risperidone for autism spectrum disorder

A rating scale for mania: reliability, validity and sensitivity

Risperidone in children with autism and serious behavioral problems.

Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders.

Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders.

Anticonvulsants: aspects of their mechanisms of action.

Disruption in the inhibitory architecture of the cell minicolumn: implications for autism.

Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases.

Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder.

Epigenetics, DNA methylation, and chromatin modifying drugs.

P2888

P304

990-998

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2009.202

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Evdokia Anagnostou

P577

2009-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40688100

http://www.w3.org/2001/XMLSchema#string

P6179

1030033637

http://www.w3.org/2001/XMLSchema#string

P698

20010551

http://www.w3.org/2001/XMLSchema#string

P921

Autism spectrum

P932

2846602

http://www.w3.org/2001/XMLSchema#string